Alza urology line will be built around Elmiron, purchased from Ivax with $75 mil. initial payment.
Executive Summary
ALZA BUILDING UROLOGY PRESENCE WITH ACQUISITION OF IVAX ELMIRON and three other urology products. Elmiron (pentosan) has been marketed since FDA approval in September 1996 for treatment of pain associated with interstitial cystitis. Alza is adding the Ivax compounds in advance of expected products from its own product development efforts. The urology field "will assume increased importance with future launches of products under development by Alza for treatment of male testosterone deficiency and urge urinary incontinence," Alza said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: